SCHEMBL6700680

SCHEMBL6700680

CC(CCO)c1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.53
HTR2A P28223 1/20 0.50
HTR2C P28335 1/20 0.50
HTR2B P41595 1/20 0.50
ACP3 P15309 2/20 0.45
CES2 O00748 1/20 0.45
DAO P14920 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
EPHX1 P07099 1/20 0.43
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16421362 0.86 PNMT (0.56) PNMTHTR2AHTR2CHTR2BACP3
SCHEMBL18211318 0.86 PNMT (0.56) PNMTHTR2AHTR2CHTR2BACP3
SCHEMBL25853626 0.86 PNMT (0.56) PNMTHTR2AHTR2CHTR2BACP3
SCHEMBL29949259 0.86 PNMT (0.56) PNMTHTR2AHTR2CHTR2BACP3
SCHEMBL1653050 0.85 TRPA1 (0.42) PNMTL3MBTL1TRPA1
SCHEMBL20821033 0.85 IDO1 (0.51) PNMTHTR2AHTR2CHTR2BACP3
SCHEMBL7929105 0.85 PNMT (0.50) PNMTHTR2AHTR2CHTR2BACP3
SCHEMBL24969798 0.83 PNMT (0.49) PNMTHTR2AHTR2CHTR2BACP3
SCHEMBL1213326 0.82 EPHX1 (0.49) PNMTHTR2AHTR2CHTR2BACP3
SCHEMBL11413371 0.81 HTR2A (0.53) PNMTHTR2AHTR2CHTR2BACP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040006081-A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2004-01-08 US disclosed
EP-1289957-A1 PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY AstraZeneca AB (SE) 2003-03-12 EP disclosed
WO-2001087839-A1 PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006081-A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity CCR5, CCR2, CCR1 PNMT 1119/4885HTR2A 800/4885HTR2C 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.